Faron Pharmaceuticals Limited (AIM:FARN) has issued 352,989 new shares following the exercise of special rights linked to its €15 million convertible bond agreement with Heights Capital Management. The shares, priced at €2.5709 each, settle a €907,500 amortisation and interest payment under the bond’s first tranche. The new shares will be admitted to trading on AIM and Nasdaq First North on or around 4 June 2025
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com